Latest research on Daptomycin

Daptomycin is a lipopeptide antibiotic that kills susceptible gram positive bacteria by disrupting their membrane potential. It is a naturally-occurring compound found in the soil bacterium Streptomyces roseosporus. Antibiotics are used in the treatment of infections caused by bacteria. They work by killing bacteria or preventing their growth. Daptomycin will not work for colds, flu, or other virus infections. It was approved in September 2003 for the treatment of complicated skin and soft tissue infections. It has a safety profile similar to other agents commonly administered to treat gram-positive infections.

Latest findings

According to Tally, Cubist produced Daptomycin, approved in September 2003, by licensing it from Eli Lilly, which shelved the new compound after concluding its potential market was only $250 million. [source, 2004]
Susceptibility test results for MRSA to Linezolid, a recently FDA-approved oxazolidinone-class antibiotic, and Daptomycin, a recently approved glycopeptide-class antibiotic, were not available at the time of this study, although neither drugs have indications to treat infections of the central nervous system. [source, 2004]
Figure 2B shows examples of ‘gene cluster family hotspots’, where metagenomes having a disproportionately high number of OTUs mapping to a specific biomedically relevant target molecule family (e.g., nocardicin, rifamycin, Bleomycin, and Daptomycin families are shown) are highlighted. [source]